Trial Profile
An Observational, Prospective, Multicentre Study to Assess the Sensitivity to Change of the SAMANTA Questionnaire in Women With Heavy Menstrual Bleeding (HMB)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Estradiol valerate/dienogest (Primary) ; Levonorgestrel (Primary) ; Medroxyprogesterone (Primary) ; Hormone replacements
- Indications Menorrhagia
- Focus Therapeutic Use
- Acronyms SAMIRA
- Sponsors Bayer
- 01 Feb 2023 Results(n=371) assessing Sensitivity to Change of the SAMANTA Questionnaire, a Heavy Menstrual Bleeding Diagnostic Tool, After 1 Year of Hormonal Treatment published in the Journal of Women's Health
- 23 Jun 2021 Status changed from active, no longer recruiting to completed.
- 24 May 2021 Planned End Date changed from 28 Apr 2021 to 28 May 2021.